Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)
Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –
Protalix BioTherapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Protalix BioTherapeutics's price to book ratio was 3.6× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 2.5× to 178.3×, with a median of 3.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | +0.7 |
| 2025 | Dec 31, 2025 | 2.9× | −1.6 |
| 2024 | Dec 31, 2024 | 4.6× | +1.3 |
| 2023 | Dec 29, 2023 | 3.2× | −159.1 |
| 2022 | Jan 31, 2022 | 162.3× | +2.0 |
| 2021 | Dec 31, 2021 | 160.3× | +136.6 |
| 2016 | Jul 29, 2016 | 23.7× | −72.7 |
| 2013 | Jan 31, 2013 | 96.4× | −1.5 |
| 2012 | Dec 31, 2012 | 97.9× | – |
See a number that looks wrong?